FDA lambasts Sri Krishna Pharma plant in new warning letter

Hyderabad

Data manipulation and integrity issues have struck again as the FDA called out India's Sri Krishna Pharmaceuticals in a newly published warning letter, highlighting several concerns it's noted for years at the drugmaker's operation.

The Hyderabad-based company's manufacturing shortfalls include incomplete data, a lack of computer system controls to ensure quality data and a lack of documented procedures to guarantee drug quality, the letter said. During the plant inspection, staff were found in multiple instances deleting data and one quality-control employee “admitted plans to fabricate sample preparation data,” the FDA’s letter said.

Sri Krishna Pharmaceuticals, which Reuters reports supplies acetaminophen and other drugs to more than 60 countries worldwide, has been on the FDA’s radar for quite a while--the regulator said it found “similar issues” there back in 2007.

Conference

The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

Now, though, the Indian drugmaker joins a host of its peers who have drawn the FDA’s ire for shoddy manufacturing systems. In recent months and years, the FDA and regulators in Europe have stepped up inspections and levied punishments for companies such as Wockhardt, Sun Pharma, Ranbaxy Labs and others. In many cases, recurring problems such as data manipulation and the potential for contamination have been found.

The FDA isn't alone in raising the alarm for the practices at Sri Krishna's plant. Last year, the Italian Medicines Agency recommended products from the facility be banned following an inspection that turned up 10 “major” issues. Inspectors found that employees were backdating testing equipment and changing test results repeatedly until arriving at an acceptable result. As Reuters notes, the FDA’s letter follows Canada’s move a year ago to block Sri Krishna imports based on data worries.

Though the Sri Krishna findings stem from an inspection more than a year ago, the FDA says the company’s response on December 24, 2014, “lacks sufficient corrective actions.” The FDA asked for a response from Sri Krishna detailing the company’s plan to fix the shortfalls.

- here's the letter
- more from Reuters

Related Articles:
Marksans the latest Indian drugmaker cited with noncompliance by European regulators
Anuh Pharma plant savaged in EMA report

Pictured is the Hyderabad financial district, courtesy of Wikipedia user Yedla70.

Read more on

Suggested Articles

Novartis' AveXis will use Catalent for some manufacturing of its newly approved gene therapy Zolgensma and more manufacturing news of note.

Pharmacy chain Rite Aid has partnered with Google to have their drug recycling stations easily searchable on Google Maps. 

Precision BioSciences says it will have a manufacturing facility for its off-the-shelf CAR-T therapies up and running in the fourth quarter.